Extracellular vesicles in stem cell-based gonadal regeneration: mechanisms, therapeutic potential, and translational challenges.
Abuna RPF., Laurindo LF., Barbalho SM., Miglino MA.
Narrative Review, published in Front Vet Sci (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Front Vet Sci (2025)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42088409
- DOI
- 10.3389/fvets.2025.1645266
Abstract (original English)
Gonadal dysfunction resulting from conditions such as premature ovarian insufficiency, chemotherapy-induced damage, or genetic disorders often leads to infertility and hormone imbalance. Although assisted reproductive technologies and hormone replacement therapies mitigate clinical symptoms, they remain incapable of reinstating native gonadal architecture and physiological function. In recent years, stem cell-based therapies, particularly those employing mesenchymal stem cells (MSCs), have demonstrated regenerative potential. However, limitations including poor engraftment, potential tumorigenicity, and ethical concerns, have accelerated the paradigm shift toward extracellular vesicles (EVs) as a safer, cell-free alternative. EVs derived from MSCs are membrane-bound nanovesicles enriched with regulatory microRNAs, proteins, and lipids that exert potent paracrine effects. These vesicles modulate apoptosis, inflammation, fibrosis, and angiogenesis. MSC-EVs can restore folliculogenesis, support spermatogenesis, and normalize hormonal profiles in preclinical models of ovarian and testicular failure. Notably, EVs derived from adipose tissue, bone marrow, placenta, or amniotic membrane exhibit regenerative potential while mitigating the risks associated with live-cell transplantation. This review synthesizes current advances in MSC-EV-based therapies for gonadal regeneration, highlig
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.